Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-03-25
DOI
10.1111/dom.14700
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Coronary Artery Calcium for the Allocation of GLP-1RA for Primary Prevention of Atherosclerotic Cardiovascular Disease
- (2021) Miguel Cainzos-Achirica et al. JACC-Cardiovascular Imaging
- Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
- (2021) Donna Shu-Han Lin et al. DIABETOLOGIA
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of LEADER and SUSTAIN 6 trials
- (2020) Lawrence A. Leiter et al. DIABETES OBESITY & METABOLISM
- Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
- (2020) Subodh Verma et al. DIABETES OBESITY & METABOLISM
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
- (2019) Donna K. Arnett et al. CIRCULATION
- Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk
- (2019) Daniella C. Terenzi et al. TRENDS IN MOLECULAR MEDICINE
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms by which GLP-1 receptor agonists and SGLT-2 inhibitors reduce cardiovascular risk
- (2019) Abhinav Sharma et al. Canadian Journal of Diabetes
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
- (2019) Vinay Garg et al. PROGRESS IN CARDIOVASCULAR DISEASES
- SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
- (2019) David A. Hess et al. Cell Metabolism
- Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events
- (2019) Subodh Verma et al. JAMA Cardiology
- Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2019) Anish Badjatiya et al. Circulation-Cardiovascular Interventions
- Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease
- (2018) Subodh Verma et al. CIRCULATION
- Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease
- (2018) Sonia S. Anand et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
- (2018) Sonia S Anand et al. LANCET
- The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
- (2018) Ketan Dhatariya et al. DIABETES CARE
- Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use
- (2018) Subodh Verma et al. CIRCULATION
- Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease
- (2018) Cecilia C. Low Wang et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
- (2018) Marc P Bonaca et al. Lancet Diabetes & Endocrinology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease
- (2016) Hanane Khoury et al. Cardiovascular Therapeutics
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of type 2 diabetes is higher in peripheral artery disease than in coronary artery disease patients
- (2015) Guenther Silbernagel et al. Diabetes & Vascular Disease Research
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
- (2015) Anoop Dinesh Shah et al. Lancet Diabetes & Endocrinology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started